Set for a major rebound on major new catalysts
Bullish pennant formed just prior to FDA putting a partial hold on Inovio's Covid-19 vaccine P2/P3 trials.
Inovio is expected to resolve the FDA's questions within the next 30 days and begin trials with "EXTENSIVE external funding" according to CEO - Dr. Joseph Kim
Inovio is expected to resolve the FDA's questions within the next 30 days and begin trials with "EXTENSIVE external funding" according to CEO - Dr. Joseph Kim
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.